Hengrui received an FDA warning letter | Jianzhi Research

A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.

wallstreetcnJul 16 23:35 ET

Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET

Hengrui's FORM 483 is not that simple | Jianzhi Research

According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.

wallstreetcnJun 7 00:22 ET

Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin

On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.

wallstreetcnMay 29 09:12 ET

Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research

Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.

wallstreetcnMay 16 20:08 ET

2024 Financial Report | Insulin Low Price Competition, Gan Li Pharmaceutical's Gains and Losses

Go out to sea

wallstreetcnApr 25 23:02 ET